Remibrutinib
Specifications
1787294-07-8CAS Number
188-778-9EC Number
N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamideIUPAC Name
C27H27F2N5O3Chemical Formula
507.5 g/molMolecular Weight
Remibrutinib; 1787294-07-8; LOU064; NVP-LOU064-NXA; LOU064-NXA; N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; I7MVZ8HDNU; N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide; Benzamide, N-(3-(6-amino-5-(2-(methyl(1-oxo-2-propen-1-yl)amino)ethoxy)-4-pyrimidinyl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluoro-; N-(3-(6-amino-5-(2-(methyl(prop-2-enoyl)amino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; RefChem:178828; Rhapsido; Remibrutinib (LOU064); N-[3-[6-Amino-5-[2-[methyl(1-oxo-2-propen-1-yl)amino]ethoxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide; Remibrutinib [INN]; Remibrutinib [USAN]; Rhapsido (TN); UNII-I7MVZ8HDNU; Remibrutinib [WHO-DD]; Remibrutinib [USAN:INN]; Remibrutinib (LOU064)?; orb1218616; orb1307808; Remibrutinib (JAN/USAN/INN); CHEMBL4483575; SCHEMBL16754888; SCHEMBL29377382; SCHEMBL29395016; SCHEMBL29564556; GTPL10457; LOU-064; YQF2712; C27H27F2N5O3; DTXSID401358943; GLXC-22285; EX-A3421; MFCD32215329; s9660; WHO 11062; AKOS040742536; example 6 [WO2015079417A1]; compound 25 [PMID: 32083858]; NCGC00689286-01; AC-36985; DA-57383; MS-29425; HY-128757; CS-0103905; D12285; F88711; T16730; US9512084, 6; F980852; N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl]-4-cyclopropyl-2-fluoro-benzamideSynonyms
